DOCSLIB.ORG

Orderly Development of Informative PART 200-GENERAL Subpart A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Orderly Development of Informative PART 200-GENERAL Subpart A 13996 RULES AND REGULATIONS Title 21-Food and Drugs Old New Old New PART 200-GENERAL Section Section Section Section Subpart A--General Provislons CHAPTER I-FOOD AND DRUG ADMIN- 133.11 ---- 211.58 3.509 ----- 201.314 Sec. ISTRATION, DEPARTMENT OF HEALTH, 133.12 ---- 211.110 3.510 ----- 201.315 200.5 Mailing of important information EDUCATION, AND WELFARE 133.13 ---- 211.60 3.512 ----- 200.31 about drugs. 133.14 ---- 211.62 [Recodification Docket No. 9] 3.513 ----- 200.7 200.7 Supplying pharmacists with Indi- ---- 211.115 3.514 ----- 201.55 133.15 cations and dosage information. SUBCHAPTER C-DRUGS: GENERAL 133.100 ____ 225.1 3.515 ----- 201.160 con- --- 22520 200.10 Contract facilities (including 3.516 ----- 250.105 133.101 sulting laboratories) Utilized as Reorganization and Republication --- 225.30 3.518 ----- 201.161 133.102 extramural facilities by pharma- 133.103 --- 225.10 The Commissioner of Food and Drugs, 132.1 ----- 207.3 ceutical manufacturer=. 133.104 --- 225A2 for the purposes of establishing an 132.2 ----- 207.20 200.11 Use of octadecylamine in steam of informative reg- 132.3 ----- 207.21 133.105 --- 225.102 lines of drug establishments. orderly development 133.106 --- 225.40 ulations for the Food and Drug Admin- 132.4 ---- 207.22 200.15 Definition of term "Insulin." 132.5 ----- 207.25 133.107 --- 225.80 istration, furnishing ample room for ..... 200.18 Use of secondhand containers for 132.6 ----- 207.30 133.108 225.58 the shipment or storage of food expansion of such regulations in years 225.110 132.7 ----- 207.31 133.109 and animal feed. ahead, and providing the public and af- 132.8 ----- 207.35 133.110 --- 225.115 --- Subpart B-ManufacturnlProcedures Affecting fected industries with regulations that 132.9 ----- 207.37 133.200 226.1 Novi DrugStatus are easy to find, read, and understand, 132.10 ---- 207.26 133.201 --- 226.20 has initiated a recodification program for 132.11 ---- 207.39 133.202 --- 226.30 200.30 Sterilization of drugs by irradia- the Code of Fed- 132.31 ---- 207.40 133.203 --- 226.10 tion. Chapter I of Title 21 of --- eral Regulations. 132.51 ---- 207.65 133.204 226.2 200.31 Timed release dosage forms. 133.1 ----- 210.3 133.205 --- 226.102 This is the ninth document in a series Subpart C--Requirements for Specific Classes or 133.2 ----- 211.1 133.206 -.... 226A0 Drugs of recodification documents that will 133.3 ----- 211.20 133.207 -- 226.80 eventually include all regulations ad- 133.4 ---- 211.30 133.208 226.58 200.50 Ophthalmic preparations and dis- ministered by the Food and Drug Ad- 133.5 ----- 211.10 133.209 --- 226.110 pensers, ministration. 133.6 ------- 211.42 133.210 --- 226.115 Subpart D-Sutability of Specific Drug This recodiflcation document repre- 133.7 ----- 211.101 133.300 --- 229.25 Components re- 133.8 ----- 211.40 138.1 ----- 299.3 200.100 Use of on bile from condemned sents a reorganization of material ----- Subchapter C-Drugs that 133.9 211.55 138.2 299.20 livers from slaughtered animals maining in ---- has general applicability, rather than 133.10 211.80 in the manufacture of drugs. 200.101 Suprarenal glands from hog car- strictly human or animal use. In addi- ' The changes being made are nonsub- casses prior to final inspection, tion certain related sections under Parts stantive in nature and for this reason 1 and 3 have been redesignated as part notice and public procedure are not pre- AuTnoRITy: Sec. 701, 52 Stat. 1055; 21 of the revised Subchapter C-Drugs: requisites to this promulgation. For the U.S.C. 371, unless otherwise noted. General. convenience of the user, the entire text of Subpart A-General Provisions The following table shows the relation- Parts 200, 201, 202, 207, 210, 211, 225, 226, ship of the CFR section numbers inder 229, 250, 290, and 299 of Subehapter C § 200.5 Mailing of important inforniu- tion about drugs. the former Subchapters A and C to their is set forth below. redesignation reflected in the new Parts Manufacturers and distributors of Dated: March 21, 1975. 200 through 299: drugs and the Food and Drug Adminis- Old New Old New S A D. FINE, tration occasionally are required to mal Section Section Section Section Associate Commissioner for Important Information about drugs to 1.100 ----- 299.5 3.21 -------- 250.102 Compliance. physicians and others responsible for public interest, such 1.101 -----.- 201.6 3.22 -------- 200.101 Therefore, 21 CFR is amended by re- patient care. In the 1.101a ---- 201.60 3.27 -------- 250.203 mail should be distinctive In appearance of Parts 1 and 3 1.102 ----- 201.50 3.28 -------- 200.50 designating portions so that It will be prolnptly recognized and Parts 132, 133, and 1.102a ---- 201.61 3.29 -------- 201.307 of Subehapter A and read. The Food and Drug Administration 1.102b ---- 201.1 3.30 -------- 201.308 138 of Subchapter C as Parts 200, 201, will make such mailings In accordance 226, 229, 250, 290, 1.102c ------ 201.51 3.35 -------- 201.303 202, 207, 210, 211, 225, with the specifications set forth In this 1.102d ---- 201.62 3.36 -------- 250.103 and 299 of Subchapter C-Drugs: Gen- section. Manufacturers and distributors 1.103 ------ 201.15 3.37 -------- 201.309 eral, and republished to read as follows: 1.104 ----- 201.10 3.40 -------- 250.201 of drugs are asked to make such mailings 1.105 ---- 202.1 33.-------- 201.310 SUBCHAPTER C-DRUGS: GENERAL as prescribed by-this section and not to 1,106(a) --- 201.5 3.44 -------- 201.311 Part use the distinctive envelopes for ordinary --- 1.106(b) 201.100 3.45 -------- 200.30 200-General mall. 1.106(c) --- 201.105 3.48 -------- 250.106 (a) Use first class mail and No. 10 1.106(d) --- 201.109 3.50 -------- 250.104 201-Labeling white envelopes. ---- 1.106(f) 201.110 3.52 -------- 250.107 (b) The name and address of the 1.106(g) --- 201.115 3.53 -------- 250.10 202-Prescription Drug Advertising or dis- 1.106(h) - 201.116 3.56 -------- 201A05 207-Registration of Producers of Drugs and agency or the drug manufacturer 1.106(1) ---- 201.117 3.61 ------- 200.18 Listing of Drugs in Commercial DIs- tributor Is to appear In the upper left 1.106(J) ---- 201.119 3.62 -------- 2994 tribution corner of the envelope. 1.106(k) --- 201.120 3.63 -------- 250.11 (c) The following statements are to 1.106(1) ---- 201.122 3.64 -------- 250.12 210-Current Good Manufacturing Practices in Manufacturing, Processing, Pack- appear in the far left third of the en- 1.106(m) --- 201.125 3.67 -------- 201.305 ing, or Holding of Drugs: General velope front, in the type and size indi- - 1.106(n) 201.127 3.71 -------- 250.100 In a rectangular spabo 1.105(o) --- 201.128 3.74 -------- 201.56 cated, centered 211-Current Good Manufacturing Practice approximately 3 inches wide and 22/ 1.107 ----- 201.150 3.76 -------- 200.10 for Finished Pharmaceuticals 1.108(a) 3.77 -------- 290.35 Inches high with an approximately %- & (b) ---- 201.16 3.81 -------- 201.200 225--Current Good Manufacturing Practice Inch-wide border in the color indicated: 1.108(c) ---- 290.6 3.84 -------- 201.410 for Medicated Feeds (1) When the information concerns 1.109 ----- 290.5 3.90 -------- 250.300 226-Current Good Manufacturing Practice a significant hazard to health, the state- 1.110 ----- 290.10 3.91 -------- 250.250 for Medicated Premixes ment: r ----- 200.15 250.109 1.115 3.94 -------- IMAPORTANT 201.300 229-Current Good Manufacturing Practice 3.3 --------- 3.95 -------- 250.110 DRUG 3.4 --------- 201.302 3.501 ----- 200.5 for Certain Other Drug Products WARNZING 3.7--------- 250.108 3.502 ----- 201.19 250-Special Requirements for Specific Hu- 3.8 --------- 250.101 3.503 ----- 201.312 man Drugs The statement shall be In three lines, all 3.11 -------- 201.301 3.505 ----- 201.313 capitals, and centered. "Important" shall Drugs 3.12 ------- 201.304 3.506 ----- 200.11 290-Controlled be in 36 point Gothic Bold type. "Drug" 3.15 -------- 201.306 3.507 _- ---201.17 29-Drugs; Official Names and Established and "Warning" shall be in 38 point 3.16 -------- 200.100 3.508 ----- 201.18 Names Gotl e Condensed type. The rectangle's FEDERAL REGISTER, VOL. 40, NO. 60-THURSDAY, MARCH 27, 1975 HeinOnline -- 40 Fed. Reg. 13996 1975 RULES AND REGULATIONS 13997 border-and -the statement therein shall Claimed Exemption for Investigational (b) The Commissloner concludes that be red. New Drug (IND), any information ob- such dangerous or potentially dangerous (2) When the information concerns tained during the inspection of an extra- practices include, but are not limited to, important changes In drug package mural facility having a specific bearing the following: labeling, the statement: on the compliance of the manufacturer's, (1) 'Some vegetable growers and IMPORTA.NT applicant's, or sponsor's product with packers employ used poultry crates for PRESCRIBING the Federal Food, Drug, and Cosmetic shipment of fresh vegetables, including INFORMATION Act. The Food and Drug Administration's cabbage and celery. Salmonella orga- The statement shall be in three lines, all position is that by the acceptance of such nisms are commonly present on dressed capitals, contract work, the extramural facility poultry and in excreta and fluid exu- and centered. "Important" shall authorizes such disclosures. dates from dressed birds. Thus wooden be in 36 point Gothic Bold type.
Load more

Recommended publications
  • Preparing for Your 5-HIAA Urine Test
    PATIENT EDUCATION patienteducation.osumc.edu Preparing for Your 5-HIAA Urine Test What is a 5-HIAA Urine Test? This test is used to help diagnose and check carcinoid tumors in the body. When the hormone serotonin breaks down in the body, it makes a waste product called 5-HIAA. The 5-HIAA urine test will show how much 5-HIAA is in your urine. You must collect urine for a 24-hour period of time to complete this test. How do I prepare for this test? Some medicines can affect the results of this test.Do not take any of the medicines listed below for 2 days before your test. Talk to your doctor if you have questions about your medicine or if you are not able to stop taking your medicine. Acetaminophen (Tylenol) Methedrine Aspirin Methyldopa ACTH MAO Inhibitors Cough syrups with guaifenesin Naproxen Ephedrine Phenacetin Fenclonine Preludin 5-FU Reserpine Heparin Robaxin Hydrazine derivatives Serotonin Imipramine Streptozocin Isocarboxazid Thorazine Isoniazid Tofranil Levodopa Zanosar This handout is for informational purposes only. Talk with your doctor or health care team if you have any questions about your care. © May 14, 2020. The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. There are certain foods and drinks that you should not eat or drink before this test. Do not eat or drink any of the items below for 4 days before the test or during the test. Avocados Grapefruit Bananas Honeydew Coffee/Tea Kiwi Cantaloupe Pineapple Dates Plantains Eggplant Plums Tomatoes / tomato products Nuts (walnuts, pecans, hickory nuts, butternuts) • Do not drink alcoholic beverages for 2 days before or during the test.
    [Show full text]
  • 付表 ⅠA 指定を受けた医薬の有効成分 Annex ⅠA Designated
    付表ⅠA 指定を受けた医薬の有効成分 Annex ⅠA Designated Pharmaceutical Active Ingredients 号(Sub-heading) 品名 Description 2818.30 アルゲルドラート algeldrate 2833.22 アルスルフ alusulf 2842.10 アルマシラート almasilate 2842.10 シマルドラート simaldrate 2842.90 硫酸アルマドラ ート almadrate sulfate 2842.90 アルマガート almagate 2842.90 カルバルドラード carbaldrate 2842.90 ヒドロタルシト hydrotalcite 2842.90 マガルドラート magaldrate 2843.30 オーラノフィン auranofin 2843.30 金チオグリカニド aurothioglycanide 2843.30 金チオりんご酸ナトリウム sodium aurothiomalate 2843.30 金チオ硫酸ナトリウム sodium aurotiosulfate 2843.90 カルボプラチン carboplatin 2843.90 シスプラチン cisplatin 2843.90 デキソルマプラチン dexormaplatin 2843.90 エンロプラチン enloplatin 2843.90 イプロプラチン iproplatin 2843.90 ロバプラチン lobaplatin 2843.90 ミボプラチン miboplatin 2843.90 ネダプラチン nedaplatin 2843.90 オルマプラチン ormaplatin 2843.90 オキサリプラチン oxaliplatin 2843.90 セブリプラチン sebriplatin 2843.90 スピロプラチン spiroplatin 2843.90 ゼニプラチン zeniplatin 2844.40 アルツモマブ altumomab 2844.40 塩化セシウム(131Cs) cesium (131 Cs) chloride 2844.40 クロルメロドリン(197Hg) chlormerodrin (197 Hg) 2844.40 シアノコバラミン(57Co) cyanocobalamin (57 Co) 2844.40 シアノコバラミン(58Co) cyanocobalamin (58 Co) 2844.40 シアノコバラミン(60Co) cyanocobalamin (60 Co) 2844.40 エチオダイズド油(131I) ethiodized oil (131 I) 2844.40 くえん酸第二鉄(59Fe)注射液 ferric (59 Fe) citrate in 2844.40 フィブリノゲン(125I) fibrinogen (125 I) 2844.40 フルデオキシグルコー ス(18F) fludeoxyglucose ( 18 F) 2844.40 フルオロドパ(18F) fluorodopa (18 F) 2844.40 くえん酸ガリウム(67Ga) gallium (67 Ga) citrate 2844.40 金コロイド(198Au) gold (198 Au), colloidal 2844.40 イオベングアン(131I) iobenguane (131 I) 2844.40 よう化人血清アルブミン(125I) iodinated (125 I) human serum albumin 2844.40 よう化人血清アルブミン(131I) iodinated
    [Show full text]
  • Datasheet Inhibitors / Agonists / Screening Libraries a DRUG SCREENING EXPERT
    Datasheet Inhibitors / Agonists / Screening Libraries A DRUG SCREENING EXPERT Product Name : Fenchlonine Catalog Number : T1447 CAS Number : 7424-00-2 Molecular Formula : C9H10CINO2 Molecular Weight : 199.63 Apprearence : Solid Melting Point : >240°C Description: Fenclonine is a selective and irreversible inhibitor of tryptophan hydroxylase, a rate-limiting enzyme in the biosynthesis of serotonin (5-HYDROXYTRYPTAMINE). Fenclonine acts pharmacologically to deplete endogenous levels of serotonin. Storage: 2 years -80°C in solvent; 3 years -20°C powder; DMSO 2 mg/mL (10 mM) Solubility Water Insoluble ( < 1 mg/ml refers to the product slightly soluble or insoluble ) Receptor (IC50) Hydroxylases In vivo Activity 4-Chloro-DL-phenylalanine(PCPA) markedly attenuates MCT(monocrotaline)-induced pulmonary vascular remodeling and lung inflammation, inhibits the expression of Tph-1 and SERT and suppresses the expression of MMP-2/-9, TIMP-1/-2, interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) and intercellular adhesion molecule-1 (ICAM-1). PCPA inhibits 5-HT by suppressing Tph-1, regulating SERT and the serotonin downstream signaling pathway[1]. Animal Experiment Animal Model: Sprague-Dawley (SD) rats Reference 1. Bai Y, et al. Int J Mol Med. 2014, 33(2):373-382. FOR RESEARCH PURPOSES ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE. Information for product storage and handling is indicated on the product datasheet. Targetmol products are stable for long term under the recommended storage conditions. Our products may be shipped under different conditions as many of them are stable in the short-term at higher or even room temperatures. We ensure that the product is shipped under conditions that will maintain the quality of the reagents.
    [Show full text]
  • Ratio of Phosphate to Amino Acids
    National Institute for Health and Care Excellence Final Neonatal parenteral nutrition [D10] Ratio of phosphate to amino acids NICE guideline NG154 Evidence reviews February 2020 Final These evidence reviews were developed by the National Guideline Alliance which is part of the Royal College of Obstetricians and Gynaecologists FINAL Error! No text of specified style in document. Disclaimer The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian. Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties. NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • X-Ray Fluorescence Analysis Method Röntgenfluoreszenz-Analyseverfahren Procédé D’Analyse Par Rayons X Fluorescents
    (19) & (11) EP 2 084 519 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: G01N 23/223 (2006.01) G01T 1/36 (2006.01) 01.08.2012 Bulletin 2012/31 C12Q 1/00 (2006.01) (21) Application number: 07874491.9 (86) International application number: PCT/US2007/021888 (22) Date of filing: 10.10.2007 (87) International publication number: WO 2008/127291 (23.10.2008 Gazette 2008/43) (54) X-RAY FLUORESCENCE ANALYSIS METHOD RÖNTGENFLUORESZENZ-ANALYSEVERFAHREN PROCÉDÉ D’ANALYSE PAR RAYONS X FLUORESCENTS (84) Designated Contracting States: • BURRELL, Anthony, K. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Los Alamos, NM 87544 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (74) Representative: Albrecht, Thomas Kraus & Weisert (30) Priority: 10.10.2006 US 850594 P Patent- und Rechtsanwälte Thomas-Wimmer-Ring 15 (43) Date of publication of application: 80539 München (DE) 05.08.2009 Bulletin 2009/32 (56) References cited: (60) Divisional application: JP-A- 2001 289 802 US-A1- 2003 027 129 12164870.3 US-A1- 2003 027 129 US-A1- 2004 004 183 US-A1- 2004 017 884 US-A1- 2004 017 884 (73) Proprietors: US-A1- 2004 093 526 US-A1- 2004 235 059 • Los Alamos National Security, LLC US-A1- 2004 235 059 US-A1- 2005 011 818 Los Alamos, NM 87545 (US) US-A1- 2005 011 818 US-B1- 6 329 209 • Caldera Pharmaceuticals, INC. US-B2- 6 719 147 Los Alamos, NM 87544 (US) • GOLDIN E M ET AL: "Quantitation of antibody (72) Inventors: binding to cell surface antigens by X-ray • BIRNBAUM, Eva, R.
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • I (Acts Whose Publication Is Obligatory) COMMISSION
    13.4.2002 EN Official Journal of the European Communities L 97/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 578/2002 of 20 March 2002 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff THE COMMISSION OF THE EUROPEAN COMMUNITIES, Nomenclature in order to take into account the new scope of that heading. Having regard to the Treaty establishing the European Commu- nity, (4) Since more than 100 substances of Annex 3 to the Com- bined Nomenclature, currently classified elsewhere than within heading 2937, are transferred to heading 2937, it is appropriate to replace the said Annex with a new Annex. Having regard to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Com- mon Customs Tariff (1), as last amended by Regulation (EC) No 2433/2001 (2), and in particular Article 9 thereof, (5) Annex I to Council regulation (EEC) No 2658/87 should therefore be amended accordingly. Whereas: (6) This measure does not involve any adjustment of duty rates. Furthermore, it does not involve either the deletion of sub- stances or addition of new substances to Annex 3 to the (1) Regulation (EEC) No 2658/87 established a goods nomen- Combined Nomenclature. clature, hereinafter called the ‘Combined Nomenclature’, to meet, at one and the same time, the requirements of the Common Customs Tariff, the external trade statistics of the Community and other Community policies concerning the (7) The measures provided for in this Regulation are in accor- importation or exportation of goods.
    [Show full text]